These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 39146803)

  • 1. Use of Tocilizumab in the treatment of chronic active antibody-mediated rejection in pediatric kidney transplant recipients.
    Sangermano M; Negrisolo S; Antoniello B; Vadori M; Cozzi E; Benetti E
    Hum Immunol; 2024 Sep; 85(5):111088. PubMed ID: 39146803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.
    Choi J; Aubert O; Vo A; Loupy A; Haas M; Puliyanda D; Kim I; Louie S; Kang A; Peng A; Kahwaji J; Reinsmoen N; Toyoda M; Jordan SC
    Am J Transplant; 2017 Sep; 17(9):2381-2389. PubMed ID: 28199785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab for the treatment of chronic antibody mediated rejection in kidney transplant recipients.
    Khairallah P; Robbins-Juarez S; Patel S; Shah V; Toma K; Fernandez H; Dube GK; King K; Mohan S; Husain SA; Morris H; Crew RJ
    Clin Transplant; 2023 Jan; 37(1):e14853. PubMed ID: 36398915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long term tolerability and clinical outcomes associated with tocilizumab in the treatment of refractory antibody mediated rejection (AMR) in pediatric renal transplant recipients.
    Pearl M; Weng PL; Chen L; Dokras A; Pizzo H; Garrison J; Butler C; Zhang J; Reed EF; Kim IK; Choi J; Haas M; Zhang X; Vo A; Chambers ET; Ettenger R; Jordan S; Puliyanda D
    Clin Transplant; 2022 Aug; 36(8):e14734. PubMed ID: 35657013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion From Calcineurin Inhibitors to Belatacept in HLA-sensitized Kidney Transplant Recipients With Low-level Donor-specific Antibodies.
    Ulloa CE; Anglicheau D; Snanoudj R; Scemla A; Martinez F; Timsit MO; Legendre C; Sberro-Soussan R
    Transplantation; 2019 Oct; 103(10):2150-2156. PubMed ID: 30720681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab in chronic active antibody-mediated rejection: rationale and protocol of an in-progress randomized controlled open-label multi-center trial (INTERCEPT study).
    Streichart L; Felldin M; Ekberg J; Mjörnstedt L; Lindnér P; Lennerling A; Bröcker V; Mölne J; Holgersson J; Daenen K; Wennberg L; Lorant T; Baid-Agrawal S
    Trials; 2024 Mar; 25(1):213. PubMed ID: 38519988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab in the treatment of active chronic humoral rejection resistant to standard therapy.
    Chamoun B; Sánchez-Sancho P; Torres IB; Gabaldon A; Perelló M; Sellarés J; Moreso F; Serón D
    Nefrologia (Engl Ed); 2022; 42(5):578-584. PubMed ID: 36717307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Tocilizumab (Anti-IL-6R) Treatment on Immunoglobulins and Anti-HLA Antibodies in Kidney Transplant Patients With Chronic Antibody-mediated Rejection.
    Shin BH; Everly MJ; Zhang H; Choi J; Vo A; Zhang X; Huang E; Jordan SC; Toyoda M
    Transplantation; 2020 Apr; 104(4):856-863. PubMed ID: 31385933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study.
    Cioni M; Nocera A; Tagliamacco A; Basso S; Innocente A; Fontana I; Magnasco A; Trivelli A; Klersy C; Gurrado A; Ramondetta M; Boghen S; Catenacci L; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Comoli P
    Transpl Int; 2019 Jan; 32(1):38-48. PubMed ID: 30076765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
    Ferreira A; Felipe C; Cristelli M; Viana L; Basso G; Stopa S; Mansur J; Ivani M; Bessa A; Ruppel P; Aguiar W; Campos E; Gerbase-DeLima M; Proença H; Tedesco-Silva H; Medina-Pestana J
    Am J Nephrol; 2017; 45(6):497-508. PubMed ID: 28511172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of Histological and Molecular Signature Response to Tocilizumab in Kidney Transplants with Chronic Active Antibody Mediated Rejection: A Case Series.
    Kumar D; Yakubu I; Safavi F; Levy M; Moinuddin I; Kimball P; Kamal L; King A; Massey D; Halloran P; Gupta G
    Kidney360; 2020 Jul; 1(7):663-670. PubMed ID: 35372943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib in the treatment of antibody-mediated rejection in pediatric kidney transplant recipients: A multicenter Midwest Pediatric Nephrology Consortium study.
    Kizilbash S; Claes D; Ashoor I; Chen A; Jandeska S; Matar RB; Misurac J; Sherbotie J; Twombley K; Verghese P
    Pediatr Transplant; 2017 May; 21(3):. PubMed ID: 28092129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tocilizumab and Active Antibody-Mediated Rejection in Kidney Transplantation: A Literature Review.
    Cabezas L; Jouve T; Malvezzi P; Janbon B; Giovannini D; Rostaing L; Noble J
    Front Immunol; 2022; 13():839380. PubMed ID: 35493469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft dysfunction in chronic antibody-mediated rejection correlates with B-cell-dependent indirect antidonor alloresponses and autocrine regulation of interferon-γ production by Th1 cells.
    Shiu KY; McLaughlin L; Rebollo-Mesa I; Zhao J; Burton H; Douthwaite H; Wilkinson H; Semik V; Dodd PC; Brookes P; Lechler RI; Hernandez-Fuentes MP; Kemper C; Dorling A
    Kidney Int; 2017 Feb; 91(2):477-492. PubMed ID: 27988211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal transplant patients with preformed anti-HLA antibodies: early biopsy findings and clinical outcomes.
    Sousa MV; Zollner RL; Mazzali M
    J Bras Nefrol; 2019 Sep; 42(2):201-210. PubMed ID: 31528982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bortezomib may stabilize pediatric renal transplant recipients with antibody-mediated rejection.
    Pearl MH; Nayak AB; Ettenger RB; Puliyanda D; Palma Diaz MF; Zhang Q; Reed EF; Tsai EW
    Pediatr Nephrol; 2016 Aug; 31(8):1341-8. PubMed ID: 27048228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-transplant HLA Antibodies and Delayed Graft Function in the Current Era of Kidney Transplantation.
    Morath C; Döhler B; Kälble F; Pego da Silva L; Echterdiek F; Schwenger V; Živčić-Ćosić S; Katalinić N; Kuypers D; Benöhr P; Haubitz M; Ziemann M; Nitschke M; Emmerich F; Pisarski P; Karakizlis H; Weimer R; Ruhenstroth A; Scherer S; Tran TH; Mehrabi A; Zeier M; Süsal C
    Front Immunol; 2020; 11():1886. PubMed ID: 32983110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subclinical Antibody-mediated Rejection After Kidney Transplantation: Treatment Outcomes.
    Parajuli S; Joachim E; Alagusundaramoorthy S; Blazel J; Aziz F; Garg N; Muth B; Mohamed M; Mandelbrot D; Zhong W; Djamali A
    Transplantation; 2019 Aug; 103(8):1722-1729. PubMed ID: 30507740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.